Circular 44/2026/TT-BYT: bioequivalence deadline for registered generics moved to 1 November 2028
The Ministry of Health has amended Circular 07/2022/TT-BYT. Registered generics that fall under the bioequivalence (BE) requirement now have until 1 November 2028 — not 1 November 2026 — to be published as having BE evidence; after that date they can no longer be made, imported or renewed without it. The circular took effect on 1 November 2026. Separately, the Drug Administration of Vietnam published its batch 4 list for 2026: 45 drugs with proven bioequivalence (Decision 1003/QD-QLD, 9 November 2026).